This investigation describes the detection of a component in Escherichia co/i capable of binding a large proportion of human antibody variable domains including otherwise highly monospecific antibodies induced by an in vivo antibody response. This interaction is of low affinity, but cross-linking of IgG molecules by, e.g. anti-immunoglobulin preparations, provides a sufficient degree of multivalency to promote a high avidity interaction. This binding which occurs both with K and A light chain-containing antibodies, appears to involve the variable region of human antibodies making it a superantigen-like activity. This is proposed based on the facts that: (i) different human antibodies of IgGl isotype appear to bind to different extents suggesting that variable domain differences determine the binding activity; and (ii) addition of soluble antigen abrogates the interaction with the E. &i-derived molecule. Future studies of the nature and possible in vivo consequences of these interactions are warranted since any superantigen activity associated with this binding might affect the human immune response occurring as a consequence of E. co/i infections.
Introduction
The immune system has, for a considerable length of time, been known to specifically interact with foreign matter (antigen) including pathogenic organisms. This interaction is characterized by phenomena such as clonal selection and affinity maturation. In particular the selected antibody repertoire is known to not only expand clones interacting well with the antigen in question but also to improve the antibody binding affinity/rate constants through a process * Corresponding author. Tel: f46 (46) 222 4322; Fax: +46 (46) 222 4200: E-mail: mats.ohlin@immun.lth.se involving somatic mutation. Recently. however, it has become clear that both viruses and bacteria produce molecules capable of interacting with a large fraction of all T and B cell antigen receptors irrespective of the antigen specificity of those receptors. Such molecules, also termed superantigens, include e.g. staphylococcal enterotoxins and mouse mammary tumor virus antigens (T cell superantigens) [ 1, 2] and staphylococcal protein A or HIV-1 gp120 (B cell superantigens) [3, 4] . These superantigen and T or B cell receptor interactions modify the immune responses of the host by inducing non-antigenspecific clonal expansion, deletion or anergy and may thus have important consequences for the host.
In this study, we have identified the presence of molecules in extracts of Escherichia coli which possess broad human antibody-binding capacity. This activity displays a low affinity for antibodies but upon cross-linking the avidity is sufficient to demonstrate substantial binding activity. Furthermore, this bacterial moiety appears to be specific for variable domains of human antibodies giving it superantigen characteristics.
Materials and methods

Antibodies
Human monoclonal antibodies specific for cytomegalovirus (CMV) pp65 and glycoprotein B (gB). tetanus toxoid and Neisseria rneningitidis opt (summarized in Table 1 ) were prepared from human X mouse heterohybridomas as tissue culture supernatants. All of them have proved to be highly monospecific in ELISA when investigated against a variety of antigens including those which frequently are recognized by polyspecific antibodies ([7,12] ; unpublished data). Affinity-purified, sheep anti-human IgG (heavy chain specific) (The Binding Site, Birmingham, UK) was conjugated to ruthenium (II) Tris-bipyridine chelate (TAG) (IGEN Inc., Rockville, MD, USA) according to the recommendations of the manufacturer. A coupling density of approximately 5 TAG molecules/IgG molecule was used. LG.71
IgGI/K [I 1, 121 IgG I /h [I 1, 121 b&l/K Antigen-antibody interactions were investigated using a recently developed electrochemiluminescence (ECL) technique [I 81 using the ORIGEN Analyzer (IGEN Inc.). In summary, this technology permits detection of interacting molecules (of which one is labelled with a luminescent moiety) following capture of the complex at the surface of an electrode. The chemiluminescent reaction is initiated electrochemically at this surface following removal of excess reagents through an automized washing procedure. In practice, antigen-coated Dynabeads (final dilution 1/30-l /60) were incubated for 30 min with human antibodies and affinity-purified, TAGlabelled sheep-anti human IgG (final concentration approximately 0.3 pg/ml) in assay diluent containing gelatin (IGEN Inc.) with continuous mixing. Human antibody concentrations were determined by an isotype-specific ELISA Ill]. In some experiments, non-bound antibodies were removed by washing with phosphate buffered saline containing 0.1% BSA prior to incubation with the TAG-labelled sheep-anti human IgG preparation. Samples were assessed in duplicates. Following addition of assay buffer the amount of antibody bound to the beads was estimated on the ORIGEN Analyzer using the ORIOS software (version 2.00; IGEN Inc.) with settings including bead capture mode, assay gain = 1000, ramp wave form (final voltage: 2800 mV), ramp rate = 4800 mV/s and no pre-operative potential .
SDS-PAGE (12.5%) semi-dry transfer to nitrocellulose and immunodetection was performed essentially as described elsewhere [6] . In some cases, the primary (human monoclonal) and secondary (peroxidase-labelled goat anti-human IgG (Zymed Labs Inc., San Francisco, CA, USA)) antibodies were incubated together on the nitrocellulose to provide cross-linking of the detecting antibody system. Bound antibodies were detected using the enhanced chemiluminescence (Amersham, Little Chalfont, Buckinghamshire, UK) technique.
Statistical analysis of the relation of V-region usage and binding capacity was performed by ANOVA using Excel 5.0 software (Microsoft, Redmond, WA, USA) running on a Macintosh LC630 computer.
Results and discussion
When initially investigating the specific binding of human monoclonal antibodies to E. co/i-derived
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IgG concentration @g/ml) Antibody (specificity) Fig. 2 . Ability of antibodies to non-specifically bind immobilized, E. co&derived Mbg58 (CMV gB, epitope AD-I) when the antibody is incubated with the antigen in the presence of a secondary, cross-linking.
TAG-labelled antibody (filled columns) but not when excess free antibody is removed by washing prior to addition of this detection reagent (hatched columns). The specific binding of AD-I specific antibodies ITC48 and ITC52 is, however. retained even if excess antibody is removed prior to addition of the detection antibody. Error bars indicate the CV of the assay. Antibody (specificity) Fig. 3 . Reactivity of human antibodies with a range of immobilized E. co/i-derived (Mbg58, UL57/2-GST and Pex/Stu) as well as other (streptavidin and BSA) antigens. Error bars indicate the CV of the assay. HM90-5 (CMV gB, epitope AD-2) immobilized to Dynabeads also mediated similar non-specific reactions (data not shown).
antigen Mbg58 (CMV gB, epitope AD-l fused to /3galactosidase) immobilized to Dynabeads using the ORIGEN Analyzer surprising binding of highly monospecific human IgG antibodies of other specificities were observed. When further investigating this phenomenon it was observed that virtually every human antibody interacted to some extent with the antigen-coated beads in the presence of the TAGlabelled, affinity-purified, cross-linking antiserum (Fig. 1) . The fact that the non-antigen-specific binding (but not the antigen-specific interaction) was not observed if excess human antibody was removed prior to addition of the cross-linking antibody ( Fig.  2 ) strongly suggested that the interaction was of low affinity and thus dependent on multivalency to provide high avidity.
To determine whether this antibody-binding activity of immobilized Mbg58 preparation was related to the CMV-derived cloned antigen, the P-galactosidase moiety of the fusion or to some other E. co&derived components, a number of other proteins were immobilized on Dynabeads and assayed for their antibody-binding capacity. It was evident that all the investigated E. c&derived preparations obtained from different laboratories contained the antibody-binding properties while immobilized bovine serum albumin did not (Fig. 3) . It was thus concluded that the low-affinity interaction of antibodies of these recombinant proteins was a property not of the recombinant proteins as such or the immobilization procedure but rather of some other E. coli-derived component frequently found in such recombinant antigen preparations. To eliminate the possibility that the binding was entirely related to an affinity for the cross-linking sheep anti-human IgG immunoglobulin preparation we investigated whether aggregated purified human IgG would by itself bind the immobilized Mbg58 preparation. It was found that purified, lightly heat-aggregated (56°C. 30 min) antibody MO6 1 (anti-CMV pp65) would indeed bind the antigen to some extent even if excess antibody was removed prior to addition of the cross-linking TAG-labelled sheep immunoglobulin preparation (data not shown).
Since the level of interaction with different human antibodies varied over more that one order of magnitude it might be anticipated that the affinity of the E. coli-derived component was directed towards the variable domain of the human antibodies. In order to investigate this assumption we tried to block this interaction by addition of soluble antigen. It was evident that antigen specific for the human antibod-
Antibody (specificity) Fig. 4 light chai n containing antibodies. The antibodies used i n this evaluation are those described i n Table  I, ies under investigation (but not unrelated control antigens) was able to efficiently block the binding of these antibodies to the immobilized E. co/i-derived component (Fig. 4) . It thus strongly suggests that the interaction of this bacterial product is directed towards the variable domains of human antibodies. It appears from the limited data that several different VH subgroups are targeted by this binding activity although the signals are somewhat stronger for antibodies belonging to subgroups VHl and VH4 as compared to VH3 and VH5, although with substantial overlap (Fig. 5) . Furthermore, this activity is not strictly dependent on any particular light chain since antibodies carrying either K and A light chains have the ability to interact with the E. c&-derived component (Fig. 5) . Further investigations will though be required to determine the precise molecular requirement for this interaction. It is, however, not likely that the binding is mediated through a lectin-activity interacting with N-linked carbohydrates residing in the antibody variable region. In fact, only two of the antibodies (the heavy chain variable regions of ITC48 and ITC63B) used in this investigation may be glycosylated in this way. In order to further characterize the antibody-binding component present in these E. co&derived preparations we tried to identify such products by immunoblot on SDS-PAGE-separated antigens. However, no antibody-binding components were identified (data not shown) even if the human antibodies were added in the presence of a enzymelabelled cross-linking antibody and despite the fact that the detection system is highly sensitive. Consequently. the exact nature of the low affinity, antibody-binding component of E. coli is still unknown. However. we suggest that it is protein related, since the superantigen activity is sensitive to proteinase K treatment (data not shown). Whether the interaction is mediated through hydrophobic surfaces exposed on incorrectly folded recombinant proteins is not known, although the absence of reactivity to denatured separated antigens in immunoblot experiments might argue against this possibility.
The biological significance of this antibody-binding capacity of E. co/i is not yet defined. However, irrespective of whether this component is actually expressed on the surface of the bacteria or only is found as an intracellular component in the live bacteria it may, apart from its possible interference in certain in vitro analytical procedures, have in vivo biological significance. Surface expressed or released (following bacterial lysis), aggregated substance may interact with and cross-link immunoglobulin surface receptors on B cells, thus mediating a B cell superantigen activity. Such signalling may provide a basis for clonal deletion/expansion/anergy associated with E. &i-related infections depending on the co-stimulatory signals that are available to the B cells, in analogy to similar HIV-l gp120-related activity [19] . Such activities might affect the outcome of diseases associated with E. c&related infections.
Analytical approaches to avoid problems associated with immunoglobulin-binding immobilized E. co/i-derived products were also investigated. Such non-antigen-specific interactions might, for example, be expected to occur if the antibody preparation contains significant amounts of antibody aggregates, which frequently accumulate following antibody purification. This reactivity may also create problems Antibody (specificity) whenever the analyte contains cross-linking components such as rheumatoid factors which are found in many serum samples. It could also be suspected that naturally multivalent antibodies. in particular 1gM may be particularly prone to such reactivities. The use of BCCP-antigen fusion proteins provides an efficient means to directly biotinylate recombinant proteins in vivo in E. coli [ 171. This approach eliminates the need for in vitro biotinylation steps that may also label for example protein contaminants found in the antigen preparation. Such a protein.
NRDI-BCCP. which just as MbgS8 expresses the AD-I epitope of CMV gB. was shown to specifically bind human AD-1 -specific antibodies when immobilized on streptavidin-coated Dynabeads (Fig. 6 ) without displaying general variable domain reactivity. This approach thus provides an alternative to in vitro-labelled antigens when using recombinant proteins in immunochemical analysis whenever variable domain binding activity of E. &-derived preparations would otherwise interfere. In conclusion. we have shown that E. coli produces a component which has the capacity to specifically interact with human immunoplobulin variable domains. This interaction is of low affinity but a substantial avidity can be achieved under cross-linking conditions. Consequently. the compound could have the ability to act as a superantigen.
